Tolerability and efficacy of A3309 in patients with chronic constipation.

The demonstration was selected as a poster of distinction , meaning that the poster was in the very best 10 percent of all AGA Institute abstracts selected for poster presentation. In addition, a poster presenting the preclinical A3309 data has been accepted. Information on the DDW session: Program Type: Poster Session Session Name: Constipation and IBS: Analysis and Treatment Session Time & Time: May 2, 2010 from 8:00 a.m. To 5:00 p.m. Title of the clinical abstract: The IBAT inhibitor A3309 – A Promising Treatment option for Sufferers with Chronic Idiopathic Constipation Title of the abstract describing preclinical findings: The IBAT inhibition by A3309 – A potential mechanism for the treatment of constipation Related StoriesScripps Florida scientists win $2.4 million to expand development of new suffering therapies The results show that A3309 was found to be safe and well tolerated and identified clear signs of enhancing colonic motility and bowel behaviors, said Magnus Simren, Principal Investigator .Chen and Moon, for instance, both abused a feature of ScholarOne: the e-mail messages delivered to scholars inviting them to review a manuscript include log-in information, and whoever receives those messages can sign into the operational system. Most other digital manuscript submission systems possess similar loopholes that can easily be hacked. The most important lesson is that incentives work. This pressure exists almost but is particularly intense in China everywhere. It is as a result no real surprise that the many inventive ways to game the peer-review system to get manuscripts released have come from China.